US 10519240
Anti-FGFR1c antibody-FGF21 fusion proteins
granted A61KA61K2039/505A61K38/00
Quick answer
US patent 10519240 (Anti-FGFR1c antibody-FGF21 fusion proteins) held by REGENERON PHARMACEUTICALS, INC. expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 10
- CPC classes
- A61K, A61K2039/505, A61K38/00, A61P, A61P3/00